AADi’s first product, ABI-009, nanoparticle albumin-bound sirolimus (rapamycin), a highly active form of sirolimus complexed with albumin, is based on the same technology as Abraxane® (nab-paclitaxel, Abraxis Bioscience, acquired by Celgene Corp in 2010 for ~$3B, 2015 sales $967M). The albumin-bound platform technology was invented and developed by Dr. Desai and colleagues at Abraxis.
ABI-009 is a clinical phase, targeted mTOR inhibitor with demonstrated safety and evidence of efficacy in a Phase I trial in patients with solid tumors. ABI-009 has a markedly different pharmacological and pharmacokinetic profile compared to any other mTOR inhibitor. Unlike other mTOR inhibitors, ABI-009 is being developed in highly select populations in diseases driven by mTOR activations. ABI-009 is licensed to AADi by Celgene for Oncology, Cardiovascular and metabolic related diseases.
Nab-rapamycin (ABI-009) Publications:
Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010;9(4):963-975.
Gasper WJ, Jimenez CA, Walker J, Conte MS, Seward K, Owens CD. Adventitial Nab-Rapamycin Injection Reduces Porcine Femoral Artery Luminal Stenosis Induced by Balloon Angioplasty via Inhibition of Medial Proliferation and Adventitial Inflammation. Circ Cardiovasc Interv. 2013.
Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, et al. Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial. Clin Cancer Res. 2013;19(19):5474-5484.